Last edition
News about "Gilead Sciences"
Gilead and LEO Pharma to Advance Development of Oral STAT6 Program
STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, amongst many others.
Gilead Sciences | 13/01/2025 | By Aishwarya
PANTHERx Rare Collaborates with Gilead Sciences for Distribution of LIVDELZI
LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Gilead Sciences | 17/08/2024 | By Aishwarya
A new paediatric drug center opened by Giliead Sciences
Development, clinical operations, legal / IP, medical affairs and regulatory teams will work together to create the company?s Global Paediatric Centre of Excellence, based in the North Dock area of the city centre.
Gilead Sciences | 12/04/2022 | By Sudeep Soparkar | 395
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy